Population pharmacokinetics of vactosertib, a new TGF-β receptor type Ι inhibitor, in patients with advanced solid tumors.
Su Young JungJi Seob YugJeffery M ClarkeTodd M BauerVicki L KeedySunjin HwangSeong-Jin KimEun Kyoung ChungJangik I LeePublished in: Cancer chemotherapy and pharmacology (2019)
The model developed in this study adequately describes the population pharmacokinetics of vactosertib in patients with advanced solid tumors. The pharmacokinetic characteristics assessed using the model would provide useful quantitative information to assist the future clinical development of vactosertib.